



## Clinical trial results:

### A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

#### Summary

EudraCT number	2017-000574-11
Trial protocol	IE GB DE HU AT LT CZ NL SK BG GR PL BE ES PT EE HR IT RO
Global end of trial date	13 December 2023

#### Results information

Result version number	v1 (current)
This version publication date	09 June 2024
First version publication date	09 June 2024

#### Trial information

##### Trial identification

Sponsor protocol code	SHP647-304
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03283085
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Shire
Sponsor organisation address	300 Shire Way, Lexington, United States, MA 02421
Public contact	Study Director, Shire, N/A +1 866-8425335, ClinicalTransparency@shire.com
Scientific contact	Study Director, Shire, N/A +1 866-8425335, ClinicalTransparency@shire.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 December 2023
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	13 December 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe UC or CD.

Protection of trial subjects:

Each participant signed an informed consent form (ICF) before participating in the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	27 February 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	South Africa: 11
Country: Number of subjects enrolled	Spain: 5
Country: Number of subjects enrolled	Ukraine: 66
Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	United States: 52
Country: Number of subjects enrolled	Argentina: 1
Country: Number of subjects enrolled	Australia: 12
Country: Number of subjects enrolled	Austria: 5
Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Bosnia and Herzegovina: 3
Country: Number of subjects enrolled	Bulgaria: 20
Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	Colombia: 3
Country: Number of subjects enrolled	Croatia: 11
Country: Number of subjects enrolled	Czechia: 15
Country: Number of subjects enrolled	Estonia: 1
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Greece: 1
Country: Number of subjects enrolled	Hungary: 24
Country: Number of subjects enrolled	Ireland: 1
Country: Number of subjects enrolled	Israel: 3
Country: Number of subjects enrolled	Italy: 22

Country: Number of subjects enrolled	Japan: 25
Country: Number of subjects enrolled	Korea, Republic of: 16
Country: Number of subjects enrolled	Lebanon: 1
Country: Number of subjects enrolled	Lithuania: 3
Country: Number of subjects enrolled	Mexico: 14
Country: Number of subjects enrolled	Netherlands: 5
Country: Number of subjects enrolled	New Zealand: 2
Country: Number of subjects enrolled	Poland: 146
Country: Number of subjects enrolled	Portugal: 7
Country: Number of subjects enrolled	Romania: 9
Country: Number of subjects enrolled	Russian Federation: 43
Country: Number of subjects enrolled	Serbia: 1
Country: Number of subjects enrolled	Slovakia: 17
Worldwide total number of subjects	557
EEA total number of subjects	296

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	11
Adults (18-64 years)	512
From 65 to 84 years	34
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants took part in the study at 225 investigative sites in 33 countries from 27 February 2018 to 13 December 2023.

### Pre-assignment

Screening details:

Participants from induction and maintenance studies of ulcerative colitis (UC) [SHP647-301 (NCT03259334), SHP647-302 (NCT03259308), and SHP647-303 (NCT03290781)] and Crohn's disease (CD) [SHP647-305 (NCT03559517), SHP647-306 (NCT03566823), and SHP647-307 (NCT03627091)] were enrolled to receive either 25 milligrams (mg) or 75 mg ontamalimab.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	UC: Ontamalimab 25 mg

Arm description:

Participants received 25 milligrams (mg) of ontamalimab solution for injection subcutaneously (SC), every 4 weeks (Q4W), for up to 3 years

Arm type	Experimental
Investigational medicinal product name	Ontamalimab 25 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Ontamalimab 25 mg, subcutaneously (SC), every 4 weeks (Q4W)

<b>Arm title</b>	UC: Ontamalimab 25mg then 75 mg
------------------	---------------------------------

Arm description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.

Arm type	Experimental
Investigational medicinal product name	Ontamalimab 75 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Ontamalimab 75 mg, subcutaneously (SC), every 4 weeks (Q4W)

Investigational medicinal product name	Ontamalimab 25 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Ontamalimab 25 mg, subcutaneously (SC), every 4 weeks (Q4W)

<b>Arm title</b>	UC: Ontamalimab 75mg
------------------	----------------------

Arm description:

Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.

Arm type	Experimental
Investigational medicinal product name	Ontamalimab 75 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Ontamalimab 75 mg, subcutaneously (SC), every 4 weeks (Q4W)

<b>Arm title</b>	CD: Ontamalimab 25 mg
------------------	-----------------------

Arm description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.

Arm type	Experimental
Investigational medicinal product name	Ontamalimab 25 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Ontamalimab 25 mg, subcutaneously (SC), every 4 weeks (Q4W)

<b>Arm title</b>	CD: Ontamalimab 25 mg then 75 mg
------------------	----------------------------------

Arm description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.

Arm type	Experimental
Investigational medicinal product name	Ontamalimab 75 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Ontamalimab 75 mg, subcutaneously (SC), every 4 weeks (Q4W)

Investigational medicinal product name	Ontamalimab 25 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Ontamalimab 25 mg, subcutaneously (SC), every 4 weeks (Q4W)

<b>Arm title</b>	CD: Ontamalimab 75 mg
------------------	-----------------------

Arm description:

Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Ontamalimab 75 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Ontamalimab 75 mg, subcutaneously (SC), every 4 weeks (Q4W)

Number of subjects in period 1	UC: Ontamalimab 25 mg	UC: Ontamalimab 25mg then 75 mg	UC: Ontamalimab 75mg
Started	89	159	268
Completed	0	117	129
Not completed	89	42	139
Adverse event, serious fatal	-	-	3
Consent withdrawn by subject	42	21	66
Physician decision	14	8	19
Adverse event, non-fatal	18	3	13
Pregnancy	-	-	1
Site Terminated by Sponsor	1	-	3
Lost to follow-up	2	-	2
Reason not Specified	-	4	8
Lack of efficacy	12	6	24

Number of subjects in period 1	CD: Ontamalimab 25 mg	CD: Ontamalimab 25 mg then 75 mg	CD: Ontamalimab 75 mg
Started	5	10	26
Completed	0	6	12
Not completed	5	4	14
Adverse event, serious fatal	1	-	-
Consent withdrawn by subject	3	3	5
Physician decision	-	-	2
Adverse event, non-fatal	-	-	5
Pregnancy	-	-	-
Site Terminated by Sponsor	-	-	-
Lost to follow-up	-	-	1
Reason not Specified	-	-	1
Lack of efficacy	1	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	UC: Ontamalimab 25 mg
Reporting group description: Participants received 25 milligrams (mg) of ontamalimab solution for injection subcutaneously (SC), every 4 weeks (Q4W), for up to 3 years	
Reporting group title	UC: Ontamalimab 25mg then 75 mg
Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.	
Reporting group title	UC: Ontamalimab 75mg
Reporting group description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.	
Reporting group title	CD: Ontamalimab 25 mg
Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.	
Reporting group title	CD: Ontamalimab 25 mg then 75 mg
Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.	
Reporting group title	CD: Ontamalimab 75 mg
Reporting group description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.	

Reporting group values	UC: Ontamalimab 25 mg	UC: Ontamalimab 25mg then 75 mg	UC: Ontamalimab 75mg
Number of subjects	89	159	268
Age Categorical Units: Subjects			

Gender categorical Units: Subjects			
Female	29	67	111
Male	60	92	157
Age categorical Units: Subjects			
<= 18 years	0	2	7
Between 18 and 65	87	148	239
>= 65 years	2	9	22
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	5	12	15
Not Hispanic or Latino	84	146	251
Unknown or Not Reported	0	1	2
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	2	4
Asian	7	14	24

Native Hawaiian or Other Pacific Islander	1	0	0
Black or African American	0	2	4
White	77	135	231
More than one race	2	2	3
Unknown or Not Reported	2	4	2

Reporting group values	CD: Ontamalimab 25 mg	CD: Ontamalimab 25 mg then 75 mg	CD: Ontamalimab 75 mg
Number of subjects	5	10	26
Age Categorical Units: Subjects			

Gender categorical Units: Subjects			
Female	1	5	14
Male	4	5	12
Age categorical Units: Subjects			
<= 18 years	0	1	1
Between 18 and 65	4	9	25
>= 65 years	1	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	1	2
Not Hispanic or Latino	5	9	24
Unknown or Not Reported	0	0	0
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	1
Asian	1	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	2
White	4	9	23
More than one race	0	0	0
Unknown or Not Reported	0	1	0

Reporting group values	Total		
Number of subjects	557		
Age Categorical Units: Subjects			

Gender categorical Units: Subjects			
Female	227		
Male	330		
Age categorical Units: Subjects			
<= 18 years	11		
Between 18 and 65	512		
>= 65 years	34		



Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	35		
Not Hispanic or Latino	519		
Unknown or Not Reported	3		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	7		
Asian	46		
Native Hawaiian or Other Pacific Islander	1		
Black or African American	8		
White	479		
More than one race	7		
Unknown or Not Reported	9		

### Subject analysis sets

Subject analysis set title	UC: Ontamalimab 25mg then 75 mg
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 3 years.	
Subject analysis set title	UC: Ontamalimab 75mg
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.	
Subject analysis set title	CD: Ontamalimab 25 mg then 75 mg
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 3 years.	
Subject analysis set title	CD: Ontamalimab 75 mg
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.	

Reporting group values	UC: Ontamalimab 25mg then 75 mg	UC: Ontamalimab 75mg	CD: Ontamalimab 25 mg then 75 mg
Number of subjects	159	268	10
Age Categorical			
Units: Subjects			

Gender categorical			
Units: Subjects			
Female	0	0	0
Male	0	0	0
Age categorical			
Units: Subjects			
<= 18 years	0	0	0
Between 18 and 65	0	0	0
>= 65 years	0	0	0
Ethnicity (NIH/OMB)			

Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	0	0	0
Unknown or Not Reported	0	0	0
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	0	0	0
More than one race	0	0	0
Unknown or Not Reported	0	0	0

<b>Reporting group values</b>	CD: Ontamalimab 75 mg		
Number of subjects	13		
Age Categorical			
Units: Subjects			

Gender categorical			
Units: Subjects			
Female	0		
Male	0		
Age categorical			
Units: Subjects			
<= 18 years	0		
Between 18 and 65	0		
>= 65 years	0		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0		
Not Hispanic or Latino	0		
Unknown or Not Reported	0		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	0		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	0		
White	0		
More than one race	0		
Unknown or Not Reported	0		

## End points

### End points reporting groups

Reporting group title	UC: Ontamalimab 25 mg
Reporting group description: Participants received 25 milligrams (mg) of ontamalimab solution for injection subcutaneously (SC), every 4 weeks (Q4W), for up to 3 years	
Reporting group title	UC: Ontamalimab 25mg then 75 mg
Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.	
Reporting group title	UC: Ontamalimab 75mg
Reporting group description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.	
Reporting group title	CD: Ontamalimab 25 mg
Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.	
Reporting group title	CD: Ontamalimab 25 mg then 75 mg
Reporting group description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.	
Reporting group title	CD: Ontamalimab 75 mg
Reporting group description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.	
Subject analysis set title	UC: Ontamalimab 25mg then 75 mg
Subject analysis set type	Full analysis
Subject analysis set description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 3 years.	
Subject analysis set title	UC: Ontamalimab 75mg
Subject analysis set type	Full analysis
Subject analysis set description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.	
Subject analysis set title	CD: Ontamalimab 25 mg then 75 mg
Subject analysis set type	Full analysis
Subject analysis set description: Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 3 years.	
Subject analysis set title	CD: Ontamalimab 75 mg
Subject analysis set type	Full analysis
Subject analysis set description: Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.	

### Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

End point title	Number of Participants With Treatment Emergent Adverse Events (TEAEs) <sup>[1]</sup>
End point description: An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs (TEAEs) were defined as AEs with start dates or worsening dates at the time of or following the first exposure to investigational product. The Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study.	
End point type	Primary

End point timeframe:

From first dose of study drug up to end of study [EOS] (up to 5.79 years)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	UC: Ontamalimab 25 mg	UC: Ontamalimab 25mg then 75 mg	UC: Ontamalimab 75mg	CD: Ontamalimab 25 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	89	159	268	5
Units: participants				
TEAE leading to death	67	122	203	4

End point values	CD: Ontamalimab 25 mg then 75 mg	CD: Ontamalimab 75 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	26		
Units: participants				
TEAE leading to death	8	17		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Serious Infections

End point title      Number of Participants With Serious Infections<sup>[2]</sup>

End point description:

Serious infections were defined as any infections that were life-threatening or those requiring hospitalization or intravenous antibiotics based on the investigator's assessment. The Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study.

End point type      Primary

End point timeframe:

From first dose of study drug up to EOS (up to 5.79 years)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	UC: Ontamalimab 25 mg	UC: Ontamalimab 25mg then 75 mg	UC: Ontamalimab 75mg	CD: Ontamalimab 25 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	89	159	268	5
Units: participants	5	4	17	0

<b>End point values</b>	CD: Ontamalimab 25 mg then 75 mg	CD: Ontamalimab 75 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	26		
Units: participants	0	0		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants With Notable Changes in Clinical Laboratory Parameters Over Time

End point title	Number of Participants With Notable Changes in Clinical Laboratory Parameters Over Time <sup>[3]</sup>
-----------------	--

End point description:

Clinical laboratory assessments included hematology, serum chemistry and urinalysis. Any notable changes in the clinical laboratory value over time based on the investigator interpretation were reported. The Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug up to EOS (up to 5.79 years)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

<b>End point values</b>	UC: Ontamalimab 25 mg	UC: Ontamalimab 25mg then 75 mg	UC: Ontamalimab 75mg	CD: Ontamalimab 25 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	89	159	268	5
Units: participants	0	0	0	0

<b>End point values</b>	CD: Ontamalimab 25 mg then 75 mg	CD: Ontamalimab 75 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	26		
Units: participants	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Discernible Changes in Electrocardiogram (ECG) Over Time

End point title	Number of Participants With Discernible Changes in Electrocardiogram (ECG) Over Time <sup>[4]</sup>
-----------------	---

End point description:

ECG included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals parameters measurement. Any discernible changes in the ECG value over time based on investigator interpretation were reported. The Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug up to EOS (up to 5.79 years)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	UC: Ontamalimab 25 mg	UC: Ontamalimab 25mg then 75 mg	UC: Ontamalimab 75mg	CD: Ontamalimab 25 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	89	159	268	5
Units: participants	0	0	0	0

End point values	CD: Ontamalimab 25 mg then 75 mg	CD: Ontamalimab 75 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	26		
Units: participants	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants With Discernible Changes in Vital Signs Over Time

End point title	Number of Participants With Discernible Changes in Vital Signs Over Time <sup>[5]</sup>
-----------------	---

End point description:

Vital sign assessments included blood pressure, pulse, respiratory rate and temperature. Any discernible changes in vital signs over time per investigator interpretation were reported.

End point type	Primary
----------------	---------

End point timeframe:

From first dose of study drug up to EOS (up to 5.79 years)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	UC: Ontamalimab 25 mg	UC: Ontamalimab 25mg then 75 mg	UC: Ontamalimab 75mg	CD: Ontamalimab 25 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	89	159	268	5
Units: participants	0	0	0	0

End point values	CD: Ontamalimab 25 mg then 75 mg	CD: Ontamalimab 75 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	26		
Units: participants	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Ulcerative Colitis With Treatment Response Over Time

End point title	Number of Participants With Ulcerative Colitis With Treatment Response Over Time <sup>[6]</sup>
-----------------	---

End point description:

Treatment response over time=clinical composite score that has decreased by greater than or equal to ( $\geq 2$ ) points &  $\geq 30$  percentage (%), with accompanying decrease in sub score for rectal bleeding (RB)  $\geq 1$  point/subscore for RB  $\leq 1$ , and/or composite score that has decreased by  $\geq 30\%$  &  $\geq 3$  points compared to baseline value for induction studies. Clinical composite score is measure consisting of sub scores RB(0-3) plus stool frequency(0-3) with higher scores=more severe disease. With implementation of protocol amendment 4 this study became a single arm study with all participants receiving 75 mg ontamalimab. Hence, only those UC participants who were receiving 75 mg ontamalimab Q4W & participating in amendment 4 were analyzed. Full Analysis Set (FAS) included all participants in the randomised set who received at least 1 dose of IP in the SHP647-304 study. Number of subjects analysed is the number of UC participants with data available for analyses.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5.79 years

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: With the implementation of amendment 4 of the protocol the study became a single arm study with all participants receiving the 75 mg dose of ontamalimab. Hence, only those UC participants who were receiving the 75 mg dose of ontamalimab every 4 weeks and participating in amendment 4 of the protocol were analyzed in this outcome measure.

End point values	UC: Ontamalimab 25mg then 75 mg	UC: Ontamalimab 75mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	120	133		
Units: participants	116	129		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Crohn's Disease With Treatment Response Over Time

End point title	Number of Participants With Crohn's Disease With Treatment Response Over Time <sup>[7]</sup>
-----------------	--

End point description:

Treatment response over time=Crohn's Disease Activity Index(CDAI)score that has decreased $\geq$ 100 points and/or simple endoscopic score for Crohn's disease(SES-CD)that has decreased by  $\geq$ 25%,both compared to baseline value for induction studies.SES-CD is simple scoring system with 4 endoscopic variables measured in same 5 ileocolonic segments as CD index of severity. Overall values on SES-CD range from 0-56,higher values=more severe disease.4 endoscopic variables are scored from 0-3 in each bowel segment:ileum,right/transverse/left colon,rectum. Presence & size of ulcers(none=0;diameter 0.1-0.5centimeter(cm)=1;0.5-2cm=2;>2cm=3);extent of ulcerated surface(none=0;<10%=1;10%-30%=2; >30%= 3);extent of affected surface(none=0;<50%=1;50%-75%=2;>75%=3);Presence & type of narrowing (none=0;single can be passed=1;multiple can be passed=2;cannot be passed=3). Only those CD participants who were part of arm groups that began receiving ontamalimab 75mg, Q4W,were analysed in this outcome measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 5.79 years

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: With implementation of protocol amendment 4 this became a single arm study with all participants receiving 75 mg ontamalimab. Hence, only those CD participants who were receiving ontamalimab 75mg Q4W and participating in amendment 4 of the protocol were analyzed.

End point values	CD: Ontamalimab 25 mg then 75 mg	CD: Ontamalimab 75 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	13		
Units: participants	6	12		

## Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug up to EOS (up to 5.79 years)

Adverse event reporting additional description:

Safety Set included all participants who received at least 1 dose of IP in the SHP647-304 study.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

### Reporting groups

Reporting group title	UC: Ontamalimab 25 mg
-----------------------	-----------------------

Reporting group description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.

Reporting group title	UC: Ontamalimab 25mg then 75 mg
-----------------------	---------------------------------

Reporting group description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.

Reporting group title	CD: Ontamalimab 75 mg
-----------------------	-----------------------

Reporting group description:

Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.

Reporting group title	CD: Ontamalimab 25 mg
-----------------------	-----------------------

Reporting group description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.

Reporting group title	CD: Ontamalimab 25 mg then 75 mg
-----------------------	----------------------------------

Reporting group description:

Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.

Reporting group title	UC: Ontamalimab 75mg
-----------------------	----------------------

Reporting group description:

Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.

Serious adverse events	UC: Ontamalimab 25 mg	UC: Ontamalimab 25mg then 75 mg	CD: Ontamalimab 75 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 89 (16.85%)	21 / 159 (13.21%)	4 / 26 (15.38%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acoustic neuroma			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bladder neoplasm			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melanocytic naevus			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibroadenoma of breast			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal neoplasm			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Vena cava thrombosis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Death			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Uterine polyp			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchiectasis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fibula fracture			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			

subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon injury			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	1 / 89 (1.12%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Ischaemic stroke			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 89 (0.00%)	2 / 159 (1.26%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia macrocytic			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Uveitis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fissure			

subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	6 / 89 (6.74%)	3 / 159 (1.89%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 8	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon dysplasia			
subjects affected / exposed	1 / 89 (1.12%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			

subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	1 / 89 (1.12%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash generalised			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria chronic			

subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Calculus urinary			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Ankylosing spondylitis			
subjects affected / exposed	1 / 89 (1.12%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 89 (1.12%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Cellulitis				
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Chronic sinusitis				
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Clostridium difficile colitis				
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Cytomegalovirus gastrointestinal infection				
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Corona virus infection				
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Herpes zoster				
subjects affected / exposed	1 / 89 (1.12%)	0 / 159 (0.00%)	0 / 26 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Infection				
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Lung abscess				
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
Perirectal abscess				

subjects affected / exposed	1 / 89 (1.12%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	1 / 89 (1.12%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	1 / 89 (1.12%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Obesity			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	CD: Ontamalimab 25 mg	CD: Ontamalimab 25 mg then 75 mg	UC: Ontamalimab 75mg
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 5 (40.00%)	2 / 10 (20.00%)	46 / 268 (17.16%)
number of deaths (all causes)	1	0	3
number of deaths resulting from adverse events	1	0	2

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acoustic neuroma			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder neoplasm			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melanocytic naevus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibroadenoma of breast			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal neoplasm			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Vena cava thrombosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Reproductive system and breast disorders			
Uterine polyp			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchiectasis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulmonary embolism			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	2 / 268 (0.75%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fibula fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon injury			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	4 / 268 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia macrocytic			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Uveitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain upper			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fissure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	10 / 268 (3.73%)
occurrences causally related to treatment / all	0 / 0	0 / 0	4 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon dysplasia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash generalised			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			



subjects affected / exposed	1 / 5 (20.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria chronic			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Calculus urinary			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Ankylosing spondylitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Appendicitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	4 / 268 (1.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic sinusitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus gastrointestinal infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Corona virus infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	2 / 268 (0.75%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			

subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	3 / 268 (1.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	3 / 268 (1.12%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	1 / 268 (0.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Obesity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	UC: Ontamalimab 25 mg	UC: Ontamalimab 25mg then 75 mg	CD: Ontamalimab 75 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	47 / 89 (52.81%)	109 / 159 (68.55%)	14 / 26 (53.85%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon adenoma			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Hypertension			
subjects affected / exposed	3 / 89 (3.37%)	12 / 159 (7.55%)	0 / 26 (0.00%)
occurrences (all)	3	12	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	4 / 89 (4.49%)	9 / 159 (5.66%)	1 / 26 (3.85%)
occurrences (all)	8	10	2
Immune system disorders			
Rubber sensitivity			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Breast pain			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Asthma-chronic obstructive pulmonary disease overlap syndrome			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 89 (0.00%)	9 / 159 (5.66%)	0 / 26 (0.00%)
occurrences (all)	0	11	0
Psychiatric disorders			
Insomnia			

subjects affected / exposed occurrences (all)	1 / 89 (1.12%) 1	2 / 159 (1.26%) 2	0 / 26 (0.00%) 0
Anxiety disorder subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	0 / 159 (0.00%) 0	0 / 26 (0.00%) 0
Investigations C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	2 / 159 (1.26%) 2	0 / 26 (0.00%) 0
Blood pressure increased subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	1 / 159 (0.63%) 1	0 / 26 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	1 / 89 (1.12%) 1	3 / 159 (1.89%) 3	0 / 26 (0.00%) 0
Migraine subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	2 / 159 (1.26%) 2	0 / 26 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	3 / 89 (3.37%) 3	16 / 159 (10.06%) 23	3 / 26 (11.54%) 3
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	7 / 89 (7.87%) 7	14 / 159 (8.81%) 22	1 / 26 (3.85%) 1
Leukopenia subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	0 / 159 (0.00%) 0	2 / 26 (7.69%) 2
Eye disorders Eyelid rash subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	0 / 159 (0.00%) 0	0 / 26 (0.00%) 0
Uveitis subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	0 / 159 (0.00%) 0	0 / 26 (0.00%) 0
Optic nerve disorder			

subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	0 / 159 (0.00%) 0	0 / 26 (0.00%) 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	3 / 89 (3.37%)	17 / 159 (10.69%)	1 / 26 (3.85%)
occurrences (all)	4	25	1
Dental caries			
subjects affected / exposed	1 / 89 (1.12%)	0 / 159 (0.00%)	1 / 26 (3.85%)
occurrences (all)	1	0	1
Crohn's disease			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	3 / 26 (11.54%)
occurrences (all)	0	0	4
Constipation			
subjects affected / exposed	0 / 89 (0.00%)	1 / 159 (0.63%)	0 / 26 (0.00%)
occurrences (all)	0	1	0
Colitis ulcerative			
subjects affected / exposed	22 / 89 (24.72%)	21 / 159 (13.21%)	0 / 26 (0.00%)
occurrences (all)	29	27	0
Anal fistula			
subjects affected / exposed	1 / 89 (1.12%)	1 / 159 (0.63%)	3 / 26 (11.54%)
occurrences (all)	1	1	4
Abdominal pain			
subjects affected / exposed	2 / 89 (2.25%)	11 / 159 (6.92%)	2 / 26 (7.69%)
occurrences (all)	2	18	2
Dry mouth			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Tongue blistering			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Irritable bowel syndrome			
subjects affected / exposed	1 / 89 (1.12%)	1 / 159 (0.63%)	1 / 26 (3.85%)
occurrences (all)	2	1	1
Frequent bowel movements			
subjects affected / exposed	1 / 89 (1.12%)	3 / 159 (1.89%)	0 / 26 (0.00%)
occurrences (all)	1	4	0

Dyspepsia subjects affected / exposed occurrences (all)	2 / 89 (2.25%) 2	10 / 159 (6.29%) 16	1 / 26 (3.85%) 1
Nausea subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	11 / 159 (6.92%) 13	0 / 26 (0.00%) 0
Skin and subcutaneous tissue disorders			
Eczema subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	2 / 159 (1.26%) 2	0 / 26 (0.00%) 0
Night sweats subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	0 / 159 (0.00%) 0	0 / 26 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Pain in extremity subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	4 / 159 (2.52%) 4	1 / 26 (3.85%) 1
Back pain subjects affected / exposed occurrences (all)	1 / 89 (1.12%) 2	11 / 159 (6.92%) 18	1 / 26 (3.85%) 1
Arthritis enteropathic subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	0 / 159 (0.00%) 0	0 / 26 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	3 / 89 (3.37%) 3	10 / 159 (6.29%) 14	1 / 26 (3.85%) 1
Infections and infestations			
Anal abscess subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	0 / 159 (0.00%) 0	1 / 26 (3.85%) 2
Influenza subjects affected / exposed occurrences (all)	2 / 89 (2.25%) 2	5 / 159 (3.14%) 5	0 / 26 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	8 / 159 (5.03%) 8	1 / 26 (3.85%) 2

Diverticulitis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	4
Corona virus infection			
subjects affected / exposed	2 / 89 (2.25%)	40 / 159 (25.16%)	4 / 26 (15.38%)
occurrences (all)	2	46	4
Bronchitis			
subjects affected / exposed	0 / 89 (0.00%)	9 / 159 (5.66%)	0 / 26 (0.00%)
occurrences (all)	0	10	0
Nasopharyngitis			
subjects affected / exposed	2 / 89 (2.25%)	18 / 159 (11.32%)	3 / 26 (11.54%)
occurrences (all)	2	23	6
Sinusitis			
subjects affected / exposed	0 / 89 (0.00%)	6 / 159 (3.77%)	1 / 26 (3.85%)
occurrences (all)	0	10	1
Respiratory tract infection viral			
subjects affected / exposed	1 / 89 (1.12%)	3 / 159 (1.89%)	0 / 26 (0.00%)
occurrences (all)	1	3	0
Respiratory tract infection			
subjects affected / exposed	1 / 89 (1.12%)	4 / 159 (2.52%)	0 / 26 (0.00%)
occurrences (all)	1	4	0
Pyelonephritis acute			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	3 / 89 (3.37%)	2 / 159 (1.26%)	0 / 26 (0.00%)
occurrences (all)	3	2	0
Tooth abscess			
subjects affected / exposed	0 / 89 (0.00%)	2 / 159 (1.26%)	0 / 26 (0.00%)
occurrences (all)	0	2	0
Upper respiratory tract infection			
subjects affected / exposed	3 / 89 (3.37%)	9 / 159 (5.66%)	1 / 26 (3.85%)
occurrences (all)	3	15	1
Viral pharyngitis			
subjects affected / exposed	0 / 89 (0.00%)	0 / 159 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0



Vestibular neuronitis subjects affected / exposed occurrences (all)	0 / 89 (0.00%) 0	0 / 159 (0.00%) 0	0 / 26 (0.00%) 0
---	---------------------	----------------------	---------------------

  

<b>Non-serious adverse events</b>	CD: Ontamalimab 25 mg	CD: Ontamalimab 25 mg then 75 mg	UC: Ontamalimab 75mg
Total subjects affected by non-serious adverse events subjects affected / exposed	3 / 5 (60.00%)	8 / 10 (80.00%)	155 / 268 (57.84%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon adenoma subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 10 (0.00%) 0	0 / 268 (0.00%) 0
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	13 / 268 (4.85%) 14
General disorders and administration site conditions Pyrexia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	13 / 268 (4.85%) 23
Immune system disorders Rubber sensitivity subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 268 (0.00%) 0
Reproductive system and breast disorders Breast pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 268 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Asthma-chronic obstructive pulmonary disease overlap syndrome subjects affected / exposed occurrences (all)  Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1  0 / 5 (0.00%) 0	0 / 10 (0.00%) 0  0 / 10 (0.00%) 0	0 / 268 (0.00%) 0  5 / 268 (1.87%) 7
Psychiatric disorders			

Insomnia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	8 / 268 (2.99%) 11
Anxiety disorder subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 268 (0.00%) 0
Investigations C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	3 / 268 (1.12%) 3
Blood pressure increased subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 10 (0.00%) 0	1 / 268 (0.37%) 1
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 10 (0.00%) 0	5 / 268 (1.87%) 5
Migraine subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	4 / 268 (1.49%) 5
Headache subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	1 / 10 (10.00%) 1	10 / 268 (3.73%) 22
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	16 / 268 (5.97%) 23
Leukopenia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	1 / 268 (0.37%) 1
Eye disorders Eyelid rash subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 268 (0.00%) 0
Uveitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 268 (0.00%) 0

Optic nerve disorder subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 268 (0.00%) 0
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	10 / 268 (3.73%) 16
Dental caries subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 10 (0.00%) 0	1 / 268 (0.37%) 1
Crohn's disease subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 268 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 10 (0.00%) 0	3 / 268 (1.12%) 4
Colitis ulcerative subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	28 / 268 (10.45%) 40
Anal fistula subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	0 / 268 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 10 (0.00%) 0	8 / 268 (2.99%) 10
Dry mouth subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	1 / 268 (0.37%) 1
Tongue blistering subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 268 (0.00%) 0
Irritable bowel syndrome subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 10 (10.00%) 1	0 / 268 (0.00%) 0
Frequent bowel movements			

subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	1 / 268 (0.37%)
occurrences (all)	0	1	1
Dyspepsia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	9 / 268 (3.36%)
occurrences (all)	0	1	11
Nausea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	5 / 268 (1.87%)
occurrences (all)	0	0	6
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	4 / 268 (1.49%)
occurrences (all)	0	1	4
Night sweats			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	1 / 268 (0.37%)
occurrences (all)	0	1	1
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences (all)	0	1	0
Back pain			
subjects affected / exposed	0 / 5 (0.00%)	2 / 10 (20.00%)	10 / 268 (3.73%)
occurrences (all)	0	3	11
Arthritis enteropathic			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences (all)	0	2	0
Arthralgia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 10 (20.00%)	13 / 268 (4.85%)
occurrences (all)	0	3	20
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences (all)	0	1	0
Influenza			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	16 / 268 (5.97%)
occurrences (all)	0	0	18
Gastroenteritis			

subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	6 / 268 (2.24%)
occurrences (all)	0	1	8
Diverticulitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	0 / 268 (0.00%)
occurrences (all)	0	0	0
Corona virus infection			
subjects affected / exposed	0 / 5 (0.00%)	2 / 10 (20.00%)	57 / 268 (21.27%)
occurrences (all)	0	2	62
Bronchitis			
subjects affected / exposed	0 / 5 (0.00%)	2 / 10 (20.00%)	8 / 268 (2.99%)
occurrences (all)	0	3	10
Nasopharyngitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	20 / 268 (7.46%)
occurrences (all)	0	0	27
Sinusitis			
subjects affected / exposed	0 / 5 (0.00%)	2 / 10 (20.00%)	4 / 268 (1.49%)
occurrences (all)	0	2	4
Respiratory tract infection viral			
subjects affected / exposed	0 / 5 (0.00%)	2 / 10 (20.00%)	4 / 268 (1.49%)
occurrences (all)	0	2	6
Respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	4 / 268 (1.49%)
occurrences (all)	0	1	4
Pyelonephritis acute			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	9 / 268 (3.36%)
occurrences (all)	0	1	13
Tooth abscess			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 10 (0.00%)	16 / 268 (5.97%)
occurrences (all)	0	0	19
Viral pharyngitis			

subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	2 / 268 (0.75%)
occurrences (all)	0	2	2
Vestibular neuronitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 10 (10.00%)	0 / 268 (0.00%)
occurrences (all)	0	1	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 December 2017	The following changes were made as per Amendment 1: 1. Revised study title to reflect inclusion of participants with Crohn's disease. 2. Updated approximate number of sites and countries in which this study will be conducted. 3. Updated the projected number of participants to reflect inclusion of participants with CD entering from Studies SHP647-305, SHP647-306, and SHP647-307. 4. Added inclusion and exclusion criteria for participants with CD entering from studies SHP647-305, SHP647-306, and SHP647-307. 5. Revised definition of safety analysis set to reflect inclusion of participants with CD entering from Studies SHP647-305, SHP647-306, and SHP647-307. 6. Added definition for FAS. 7. Revised expected duration of study to reflect inclusion of participants with CD. 5. Updated inclusion and exclusion criteria.
14 September 2018	The following changes were made as per Amendment 2: 1. Added text to clarify that a participant's maximum duration of treatment is expected to be 7 years, subject to local or country requirements. 2. Updated exclusion criteria. 3. Added pregnancy as a reason that a participant may be withdrawn from study treatment.
06 November 2019	The following changes were made as per Amendment 3: 1. Updated total sample size projected for the enrollment in the study. 2. Added inclusion and exclusion criteria for UC participants entering directly. 3. Added visit numbers to the schedules of assessments. 4. Updated endpoints to reflect inclusion of direct-entry UC participants.
21 September 2020	The following changes were made as per Amendment 4: 1. Removed direct entry of participants with UC. 2. Changed the safety follow-up period from 16 weeks to 12 weeks. 3. Revised total sample size projection. 4. Updated the number of sites and the countries in which the study will be conducted. 5. Added a secondary objective to evaluate the maintenance of response to long-term treatment with ontamalimab as measured by the clinical composite score (for participants with UC) or CDAI score (for participants with CD) and biomarkers, with or without endoscopy. 6. Updated the time of study completion from approximately 7 years to no more than 3 years (ie, a participant's participation is not expected to extend beyond 2023). 7. Updated inclusion and criteria.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported